Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Feb 18, 2025 · CIK: 882361
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Aptose Biosciences filed an 8-K on Feb 18, 2025, with financial updates.
AI Summary
Aptose Biosciences Inc. filed an 8-K on February 18, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the biological products sector.
Why It Matters
This filing provides important updates and disclosures for investors regarding Aptose Biosciences Inc.'s financial status and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically contains standard disclosures and financial information without immediate significant operational changes.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- February 18, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 18, 2025.
What is Aptose Biosciences Inc.'s Standard Industrial Classification code?
Aptose Biosciences Inc.'s Standard Industrial Classification code is 2836, for Biological Products (No Diagnostic Substances).
What were Aptose Biosciences Inc.'s former company names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
In which jurisdiction is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 18, 2025 regarding Aptose Biosciences Inc. (APTOF).